- Home
- NSSC vs PRAX Comparison
NSSC vs PRAX Comparison
Compare NSSC & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NSSC | PRAX |
|---|---|---|
| Founded | 1969 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 4.0B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | NSSC | PRAX |
|---|---|---|
| Price | $42.17 | $294.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 14 |
| Target Price | $47.50 | ★ $373.79 |
| AVG Volume (30 Days) | 379.3K | ★ 811.0K |
| Earning Date | 02-02-2026 | 11-05-2025 |
| Dividend Yield | ★ 1.33% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.23 | N/A |
| Revenue | ★ $186,786,000.00 | $7,463,000.00 |
| Revenue This Year | $13.13 | N/A |
| Revenue Next Year | $9.55 | $12,467.71 |
| P/E Ratio | $34.17 | ★ N/A |
| Revenue Growth | N/A | ★ 364.98 |
| 52 Week Low | $19.00 | $26.70 |
| 52 Week High | $48.12 | $317.72 |
Technical Indicators
Market Signals| Indicator | NSSC | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 51.62 | 68.78 |
| Support Level | $41.57 | $285.95 |
| Resistance Level | $44.01 | $317.72 |
| Average True Range (ATR) | 1.18 | 13.26 |
| MACD | -0.03 | -0.10 |
| Stochastic Oscillator | 39.07 | 66.54 |
Price Performance
Historical ComparisonAbout NSSC NAPCO Security Technologies Inc.
NAPCO Security Technologies Inc manufactures security products, encompassing access control systems, door-locking products, intrusion and fire alarm systems and video surveillance products. Its products are used for various applications which includes alarm systems like automatic communicators, combination control panels/digital communicators and digital keypad systems, fire alarm control panel and area detectors mainly used for commercial, residential, institutional, industrial and governmental uses. Geographically, the company derives a majority of its revenue from the United States.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.